Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Long-Term Investments (2021 - 2025)

Precision Biosciences (DTIL) has disclosed Long-Term Investments for 5 consecutive years, with $744000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments changed N/A to $744000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $744000.0, a N/A change, with the full-year FY2024 number at $3.2 million, changed 0.0% from a year prior.
  • Long-Term Investments was $744000.0 for Q3 2025 at Precision Biosciences, roughly flat from $744000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $3.2 million in Q4 2023 to a low of $744000.0 in Q2 2025.
  • A 5-year average of $2.3 million and a median of $2.9 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 285.8% in 2024, then plummeted 76.79% in 2025.
  • Precision Biosciences' Long-Term Investments stood at $3.1 million in 2021, then fell by 16.66% to $2.6 million in 2022, then increased by 24.46% to $3.2 million in 2023, then changed by 0.0% to $3.2 million in 2024, then tumbled by 76.79% to $744000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Long-Term Investments are $744000.0 (Q3 2025), $744000.0 (Q2 2025), and $3.2 million (Q1 2025).